iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L.

Niemoeller E, Souhami E, Wu Y, Jensen KH

Diabetes therapy : research, treatment and education of diabetes and related disorders16 Nov 2017Cited by 9 (Europe PMC)

PMID29143919PMCIDPMC5801222DOI10.1007/s13300-017-0336-6PepBankPUB-29143919

Read at source PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In diabetes trial completers, HbA1c fell 1.7% from screening with iGlarLixi versus 1.1% with insulin glargine (p < 0.0001).
In plain wordsIn diabetes trial completers, HbA1c fell more from screening with iGlarLixi than insulin glargine.
Peptide
Lixisenatide
Outcome
DecreaseOverall HbA1c reduction from screening
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
HbA1c LS mean reduction from screening to week 30
−1.7%
iGlarLixi, overall
HbA1c LS mean reduction from screening to week 30
−1.1%
iGlar, overall
P value
< 0.0001
iGlarLixi versus iGlar, overall
Source sentences
Summary
HbA_1c reductions (least squares mean) from screening to Week 30 were greater for iGlarLixi than iGlar, both overall (- 1.7 vs. - 1.1%) and in all subgroups (HbA_1c ≤ 8%, 8% 1c ≤ 9%, and HbA_1c > 9%): - 1.1, - 1.4, - 2.4 (iGlarLixi) vs. - 0.5, - 1.0, - 1…
2 context sentences(design, population, supporting numbers)
Summary · context
In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks.
Summary · context
In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA_1c) levels from screening, both for the overall category and for screening HbA_1c subcategories.
Report a problemFND-2914391901
02HumanNon-randomized trialEfficacy outcome
In diabetes completers with screening HbA1c ≤8%, HbA1c fell from screening by 1.1% with iGlarLixi versus 0.5% with insulin glargine.
In plain wordsIn completers with the lowest screening HbA1c category, HbA1c fell more from screening with iGlarLixi than insulin glargine.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c reduction, screening HbA1c ≤8%
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
HbA1c LS mean reduction from screening to week 30
−1.1%
iGlarLixi, screening HbA1c <= 8%
HbA1c LS mean reduction from screening to week 30
−0.5%
iGlar, screening HbA1c <= 8%
P value
< 0.0001
iGlarLixi versus iGlar, screening HbA1c <= 8%
Source sentences
Summary
HbA_1c reductions (least squares mean) from screening to Week 30 were greater for iGlarLixi than iGlar, both overall (- 1.7 vs. - 1.1%) and in all subgroups (HbA_1c ≤ 8%, 8% 1c ≤ 9%, and HbA_1c > 9%): - 1.1, - 1.4, - 2.4 (iGlarLixi) vs. - 0.5, - 1.0, - 1…
2 context sentences(design, population, supporting numbers)
Summary · context
In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks.
Summary · context
In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA_1c) levels from screening, both for the overall category and for screening HbA_1c subcategories.
Report a problemFND-2914391902
03HumanNon-randomized trialEfficacy outcome
In diabetes completers with screening HbA1c >8% to ≤9%, HbA1c fell from screening by 1.4% with iGlarLixi versus 1.0% with insulin glargine.
In plain wordsIn completers with the middle screening HbA1c category, HbA1c fell more from screening with iGlarLixi than insulin glargine.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c reduction, screening HbA1c >8% to ≤9%
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
HbA1c LS mean reduction from screening to week 30
−1.4%
iGlarLixi, screening HbA1c > 8% to <= 9%
HbA1c LS mean reduction from screening to week 30
−1%
iGlar, screening HbA1c > 8% to <= 9%
P value
< 0.0001
iGlarLixi versus iGlar, screening HbA1c > 8% to <= 9%
Source sentences
Summary
HbA_1c reductions (least squares mean) from screening to Week 30 were greater for iGlarLixi than iGlar, both overall (- 1.7 vs. - 1.1%) and in all subgroups (HbA_1c ≤ 8%, 8% 1c ≤ 9%, and HbA_1c > 9%): - 1.1, - 1.4, - 2.4 (iGlarLixi) vs. - 0.5, - 1.0, - 1…
2 context sentences(design, population, supporting numbers)
Summary · context
In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks.
Summary · context
In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA_1c) levels from screening, both for the overall category and for screening HbA_1c subcategories.
Report a problemFND-2914391903
04HumanNon-randomized trialEfficacy outcome
In diabetes completers with screening HbA1c >9%, HbA1c fell from screening by 2.4% with iGlarLixi versus 1.8% with insulin glargine.
In plain wordsIn completers with the highest screening HbA1c category, HbA1c fell more from screening with iGlarLixi than insulin glargine.
Peptide
Lixisenatide
Outcome
DecreaseHbA1c reduction, screening HbA1c >9%
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
HbA1c LS mean reduction from screening to week 30
−2.4%
iGlarLixi, screening HbA1c > 9%
HbA1c LS mean reduction from screening to week 30
−1.8%
iGlar, screening HbA1c > 9%
P value
< 0.0001
iGlarLixi versus iGlar, screening HbA1c > 9%
Source sentences
Summary
HbA_1c reductions (least squares mean) from screening to Week 30 were greater for iGlarLixi than iGlar, both overall (- 1.7 vs. - 1.1%) and in all subgroups (HbA_1c ≤ 8%, 8% 1c ≤ 9%, and HbA_1c > 9%): - 1.1, - 1.4, - 2.4 (iGlarLixi) vs. - 0.5, - 1.0, - 1…
2 context sentences(design, population, supporting numbers)
Summary · context
In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks.
Summary · context
In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA_1c) levels from screening, both for the overall category and for screening HbA_1c subcategories.
Report a problemFND-2914391904
05HumanNon-randomized trialEfficacy outcome
In diabetes completers, 59.9% reached HbA1c <7% with iGlarLixi versus 31.2% with insulin glargine at week 30.
In plain wordsIn diabetes completers, more reached the HbA1c target with iGlarLixi than insulin glargine at week 30.
Peptide
Lixisenatide
Outcome
IncreaseOverall HbA1c target attainment
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
Patients achieving HbA1c < 7%
59.9%
iGlarLixi, overall, week 30
Patients achieving HbA1c < 7%
31.2%
iGlar, overall, week 30
Source sentences
Summary
More patients achieved an HbA_1c of < 7% with iGlarLixi than with iGlar, both overall (59.9 vs. 31.2%) and within each subgroup [74.2, 54.7, 52.2 (iGlarLixi) vs. 37.2, 31.6, 23.5% (iGlar), respectively].
2 context sentences(design, population, supporting numbers)
Summary · context
In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks.
Summary · context
In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA_1c) levels from screening, both for the overall category and for screening HbA_1c subcategories.
Report a problemFND-2914391905
06HumanNon-randomized trialEfficacy outcome
In diabetes completers with screening HbA1c ≤8%, 74.2% reached HbA1c <7% with iGlarLixi versus 37.2% with insulin glargine.
In plain wordsIn completers with the lowest screening HbA1c category, more reached target HbA1c with iGlarLixi than insulin glargine.
Peptide
Lixisenatide
Outcome
IncreaseHbA1c target, screening HbA1c ≤8%
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
Patients achieving HbA1c < 7%
74.2%
iGlarLixi, screening HbA1c <= 8%, week 30
Patients achieving HbA1c < 7%
37.2%
iGlar, screening HbA1c <= 8%, week 30
Source sentences
Summary
More patients achieved an HbA_1c of < 7% with iGlarLixi than with iGlar, both overall (59.9 vs. 31.2%) and within each subgroup [74.2, 54.7, 52.2 (iGlarLixi) vs. 37.2, 31.6, 23.5% (iGlar), respectively].
3 context sentences(design, population, supporting numbers)
Summary · context
according to HbA_1c subcategory at screening (HbA_1c ≤ 8%, 8% 1c ≤ 9%, and HbA_1c > 9%).
Summary · context
In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks.
Summary · context
In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA_1c) levels from screening, both for the overall category and for screening HbA_1c subcategories.
Report a problemFND-2914391906
07HumanNon-randomized trialEfficacy outcome
In diabetes completers with screening HbA1c >8% to ≤9%, 54.7% reached HbA1c <7% with iGlarLixi versus 31.6% with insulin glargine.
In plain wordsIn completers with the middle screening HbA1c category, more reached target HbA1c with iGlarLixi than insulin glargine.
Peptide
Lixisenatide
Outcome
IncreaseHbA1c target, screening HbA1c >8% to ≤9%
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
Patients achieving HbA1c < 7%
54.7%
iGlarLixi, screening HbA1c > 8% to <= 9%, week 30
Patients achieving HbA1c < 7%
31.6%
iGlar, screening HbA1c > 8% to <= 9%, week 30
Source sentences
Summary
More patients achieved an HbA_1c of < 7% with iGlarLixi than with iGlar, both overall (59.9 vs. 31.2%) and within each subgroup [74.2, 54.7, 52.2 (iGlarLixi) vs. 37.2, 31.6, 23.5% (iGlar), respectively].
3 context sentences(design, population, supporting numbers)
Summary · context
according to HbA_1c subcategory at screening (HbA_1c ≤ 8%, 8% 1c ≤ 9%, and HbA_1c > 9%).
Summary · context
In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks.
Summary · context
In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA_1c) levels from screening, both for the overall category and for screening HbA_1c subcategories.
Report a problemFND-2914391907
08HumanNon-randomized trialEfficacy outcome
In diabetes completers with screening HbA1c >9%, 52.2% reached HbA1c <7% with iGlarLixi versus 23.5% with insulin glargine.
In plain wordsIn completers with the highest screening HbA1c category, more reached target HbA1c with iGlarLixi than insulin glargine.
Peptide
Lixisenatide
Outcome
IncreaseHbA1c target, screening HbA1c >9%
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
Patients achieving HbA1c < 7%
52.2%
iGlarLixi, screening HbA1c > 9%, week 30
Patients achieving HbA1c < 7%
23.5%
iGlar, screening HbA1c > 9%, week 30
Source sentences
Summary
More patients achieved an HbA_1c of < 7% with iGlarLixi than with iGlar, both overall (59.9 vs. 31.2%) and within each subgroup [74.2, 54.7, 52.2 (iGlarLixi) vs. 37.2, 31.6, 23.5% (iGlar), respectively].
3 context sentences(design, population, supporting numbers)
Summary · context
according to HbA_1c subcategory at screening (HbA_1c ≤ 8%, 8% 1c ≤ 9%, and HbA_1c > 9%).
Summary · context
In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks.
Summary · context
In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA_1c) levels from screening, both for the overall category and for screening HbA_1c subcategories.
Report a problemFND-2914391908
09HumanNon-randomized trialSafety outcome
In diabetes completers across screening HbA1c categories, hypoglycemia risk did not increase with iGlarLixi versus insulin glargine during treatment.
In plain wordsIn diabetes completers across screening categories, hypoglycemia risk did not increase with iGlarLixi versus insulin glargine.
Peptide
Lixisenatide
Outcome
Direction not reportedHypoglycemia risk across screening categories
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Source sentences
Summary
In all HbA_1c screening categories, the risk of hypoglycemia was not increased with iGlarLixi versus iGlar during the treatment phase.
2 context sentences(design, population, supporting numbers)
Summary · context
In the LixiLan-L trial, patients experienced a 6-week run-in with insulin glargine U100 (iGlar) as part of the screening phase, followed by treatment with a fixed-ratio combination of iGlar + lixisenatide (iGlarLixi) or iGlar alone over 30 weeks.
Summary · context
In the study reported here, we investigated the achievement of glycemic control in those who completed the 30-week LixiLan-L trial, as assessed by change in glycated hemoglobin (HbA_1c) levels from screening, both for the overall category and for screening HbA_1c subcategories.
Report a problemFND-2914391909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02058160

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Sanofin = 736Jan 2014 to Jul 2015

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 9 May 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.